Tirzepatide
Tirzepatide is a novel synthetic peptide representing a groundbreaking advancement in metabolic medicine through its dual agonist activity at glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Originally developed as a dual incretin receptor agonist, tirzepatide represents a paradigm shift in obesity and diabetes management by addressing both glycemic control and weight management through complementary mechanisms that offer superior efficacy compared to single-receptor targeting approaches.
This peptide has gained considerable attention in endocrinology and obesity medicine due to its demonstrated efficacy in achieving substantial weight loss (15-22% of body weight) and exceptional glycemic control in patients with type 2 diabetes and obesity. Tirzepatide exhibits unique properties through its dual incretin-mimetic mechanism and maintains bioactivity across various metabolic pathways, making it distinctive among therapeutic peptides with FDA approval for both diabetes and weight management applications.
Overview
Tirzepatide incorporates structural modifications including a fatty acid side chain that enables albumin binding, significantly extending the peptide's half-life compared to native incretin hormones. The peptide is metabolized through proteolytic degradation and renal elimination, with detectability and therapeutic effects persisting for up to one week post-administration using standard monitoring methods.
Chemical structure & Properties
- Molecular Formula: C225H348N48O68
- Molecular Weight: 4,813 Da
- Sequence: 39-residue peptide built on a GIP backbone, with Aib substitutions at positions 2 and 13 and a lysine-linked fatty-acid chain for albumin binding.
- Half-life: Approximately 5 days (enabling once-weekly dosing)
- Stability: Stable peptide formulation requiring refrigeration
Mechanism of Action
Tirzepatide exerts its therapeutic effects through multiple interconnected molecular pathways:
Areas Investigated in
the Research Literature
Current Clinical Evidence
Safety Profile and Considerations
Regulatory Status and Legal Considerations
Regulatory information current as of 28 August 2026. This is a summary, not legal or medical advice, and status can change.
FDA Status
- Classification: FDA-approved prescription medication
- Approval Status: Approved for type 2 diabetes (Mounjaro®) and chronic weight management (Zepbound®); Zepbound® was also approved for moderate-to-severe obstructive sleep apnea in adults with obesity in December 2024.
- Approval Dates: Diabetes approval May 2022, weight management approval November 2023
- Regulatory Position: Full FDA approval with established safety and efficacy
International Status
- EMA: Approved for diabetes management in European Union
- Health Canada: Approved for diabetes management
- Global Markets: Multiple international regulatory approvals ongoing
COMPOUNDING STATUS
- Shortage Compounding: Tirzepatide shortage-related compounding was permitted during the FDA shortage period.
- Shortage Resolution: FDA determined the tirzepatide injection shortage was resolved in December 2024; enforcement discretion allowed certain compounding through March 19, 2025 for 503B facilities.
- Current Status: In April 2026, FDA proposed excluding tirzepatide from the 503B bulk drug substances list.
Legal Availability
- Commercial Status: FDA approved as a prescription medication under brand names. Compounded versions are governed by separate and changing rules.
- Market Presence: Available through licensed healthcare providers and pharmacies
- Quality Control: Manufactured under strict pharmaceutical quality standards
- Clinical Use: Standard medical practice for approved indications
Conclusion
What the evidence supports
Tirzepatide is a dual GIP and GLP-1 receptor agonist supported by large controlled trials in type 2 diabetes and chronic weight management. It is FDA approved as Mounjaro for type 2 diabetes and Zepbound for chronic weight management and, since December 2024, for moderate-to-severe obstructive sleep apnea in adults with obesity. Shortage-related compounding was permitted only during the FDA shortage, which has since been resolved. This page summarizes the published research and nothing further.
Tirzepatide SCIENTIFIC
DATA SUMMARY
About this library
This library is published for education. It summarizes published research on compounds studied in this field. Many have no approved medical use, and several cannot lawfully be compounded in the United States. The presence of a page here does not mean Paragon offers that compound. Nothing on these pages is an offer to treat.
This page is general education about a compound studied in this field. Nothing here is medical advice, a recommendation, or an offer to prescribe or supply. A page appearing in this library does not mean Paragon Sports Medicine offers that compound.
Disclaimer: This information is provided for educational purposes only and does not constitute medical advice. Tirzepatide is FDA-approved for type 2 diabetes and chronic weight management under the brand names Mounjaro® and Zepbound®. Patients should consult with qualified healthcare providers before considering any peptide therapy.
Statements on this page have not been evaluated by the FDA and are not intended to diagnose, treat, cure, or prevent any disease. Many peptides described here are not FDA approved for the uses discussed, and some cannot lawfully be compounded in the United States. Nothing on this page is medical advice or a recommendation for any individual. Whether any therapy is appropriate depends on your history, your laboratory results, and a clinical evaluation. Individual results vary. This page is published for education. Use of this site does not create a physician-patient relationship.